Chargement en cours...
Trimetazidine improves hepatic lipogenesis and steatosis in non-alcoholic fatty liver disease via AMPK-ChREBP pathway
Clinical studies have demonstrated that trimetazidine (TMZ) possesses a synergistic hypolipidemic effect together with statins, but the underlying mechanism remains to be elucidated. The present study aimed to investigate the role of TMZ in non-alcoholic fatty liver disease (NAFLD). By investigating...
Enregistré dans:
| Publié dans: | Mol Med Rep |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
D.A. Spandidos
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7411376/ https://ncbi.nlm.nih.gov/pubmed/32705195 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2020.11309 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|